TG Therapeutics, Inc. (TGTX)
56.90
+0.81
(+1.44%)
USD |
NASDAQ |
Sep 02, 16:00
56.89
-0.01
(-0.02%)
Pre-Market: 08:13
TG Therapeutics Research and Development Expense (TTM) : 225.80M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 225.80M |
| March 31, 2026 | 162.25M |
| December 31, 2025 | 160.22M |
| September 30, 2025 | 142.90M |
| June 30, 2025 | 122.16M |
| March 31, 2025 | 107.93M |
| December 31, 2024 | 94.29M |
| September 30, 2024 | 87.86M |
| June 30, 2024 | 82.48M |
| March 31, 2024 | 93.05M |
| December 31, 2023 | 76.19M |
| September 30, 2023 | 88.38M |
| June 30, 2023 | 94.43M |
| March 31, 2023 | 93.18M |
| December 31, 2022 | 125.35M |
| September 30, 2022 | 158.36M |
| June 30, 2022 | 189.53M |
| March 31, 2022 | 207.53M |
| December 31, 2021 | 222.58M |
| September 30, 2021 | 202.89M |
| June 30, 2021 | 201.39M |
| March 31, 2021 | 192.97M |
| December 31, 2020 | 165.90M |
| September 30, 2020 | 153.88M |
| June 30, 2020 | 161.40M |
| Date | Value |
|---|---|
| March 31, 2020 | 157.82M |
| December 31, 2019 | 154.18M |
| September 30, 2019 | 175.51M |
| June 30, 2019 | 150.92M |
| March 31, 2019 | 156.76M |
| December 31, 2018 | 159.39M |
| September 30, 2018 | 133.11M |
| June 30, 2018 | 126.86M |
| March 31, 2018 | 114.87M |
| December 31, 2017 | 102.53M |
| September 30, 2017 | 98.82M |
| June 30, 2017 | 93.47M |
| March 31, 2017 | 80.30M |
| December 31, 2016 | 69.23M |
| September 30, 2016 | 62.20M |
| June 30, 2016 | 51.98M |
| March 31, 2016 | 49.71M |
| December 31, 2015 | 47.71M |
| September 30, 2015 | 47.59M |
| June 30, 2015 | 49.71M |
| March 31, 2015 | 45.29M |
| December 31, 2014 | 40.09M |
| September 30, 2014 | 28.71M |
| June 30, 2014 | 18.32M |
| March 31, 2014 | 16.50M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Krystal Biotech, Inc. | 53.39M |
| MAIA Biotechnology, Inc. | 17.40M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| BioMarin Pharmaceutical, Inc. | 766.68M |
| Cytokinetics, Inc. | 384.41M |